Continuing Medical Education (CME) Credits
The educational objectives of this conference are to describe and discuss the latest clinical and research advances in Pulmonary Medicine.
Upon completion of this conference, the attendees should be able to:
- Describe the role of metabolism and the inflammasome on Cystic Fibrosis patients with pseudomonas colonization; consider novel therapies targeting the inflammasome;
- Understand the changes to lung immune cell metabolism in patients with asthma;
- Understand the changes to lung immune cell metabolism in patients with COPD;
- Recognize the implications of beta agonist and inhaled steroid therapy on immune function and weigh the risks and benefits of therapy for asthmatic and COPD patients;
- Recognize metabolism of immune cells in the containment and elimination of cancer as new immunotherapy for cancer is becoming widely used.
The target audience for this conference is practicing physicians, nurses, fellows-in-training, allied health personnel, basic and translational researchers, public health experts, industry scientists, and any other health care or academic professional with a major clinical or research interest in pulmonary medicine.
Further, because the University of Pittsburgh and UPMC are internationally recognized leaders in pulmonary and critical care and research, the conference will also enable providers on a treatment team to contribute specialized knowledge of metabolic and immune processes happening in specific disease states to inform their team and bring consensus to therapeutic strategy for patients with these diseases.
This activity is approved for the following credit: AMA PRA Category 1 CreditTM, ANCC, and AAPA Category 1 CME. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.